The role of PALB2 in the DNA damage response and cancer predisposition

International Journal of Molecular Sciences

Volumn 18, Issue 9, 2017, Pages

  Nepomuceno, Thales C ^a   De Gregoriis, Giuliana ^a   de Oliveira, Francisco M Bastos ^b   Suarez Kurtz, Guilherme ^a   Monteiro, Alvaro N ^c   Carvalho, Marcelo A ^a,d  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d INSTITUTO FEDERAL DE EDUCAÇÃO   (Brazil)

Author keywords

Breast Cancer 1 (BRCA1); Breast Cancer 2 (BRCA2); Cancer predisposition; Deoxyribonucleic acid (DNA) damage response; DNA double strand break; Fanconi anemia; Fanconi Anemia Group N protein (FANCN); Homologous recombination; Partner and Localizer of BRCA2 (PALB2)

Indexed keywords

BRCA2 PROTEIN; CHECKPOINT KINASE RAD3; PALB2 PROTEIN, HUMAN; PARTNER AND LOCALIZER OF BRCA2;

BREAST CANCER; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHROMOSOME; DNA DAMAGE RESPONSE; FANCONI ANEMIA; GENE CONTROL; HOMOLOGOUS RECOMBINATION; HUMAN; PROTEIN STRUCTURE; REVIEW; ANIMAL; DNA DAMAGE; GENETIC PREDISPOSITION; GENETICS; GENOMIC INSTABILITY; METABOLISM; NEOPLASM; PATHOLOGY; RECOMBINATION REPAIR;

ANIMALS; DNA DAMAGE; FANCONI ANEMIA COMPLEMENTATION GROUP N PROTEIN; GENETIC PREDISPOSITION TO DISEASE; GENOMIC INSTABILITY; HUMANS; NEOPLASMS; RECOMBINATIONAL DNA REPAIR;

EID: 85028767746     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18091886     Document Type: Review

References (148)

1. Hall, J.M.; Lee, M.K.; Newman, B.; Morrow, J.E.; Anderson, L.A.; Huey, B.; King, M.-C. Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21. Science 1990, 250, 1684-1689, doi:10.1126/science.2270482.
2. Miki, Y.; Swensen, J.; Shattuck-Eidens, D.; Futreal, P.A.; Harshman, K.; Tavtigian, S.; Liu, Q.; Cochran, C.; Bennett, L.M.; Ding, W. A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1. Science 1994, 266, 66-71, doi:10.1126/science.7545954.
3. Wooster, R.; Neuhausen, S.L.; Mangion, J.; Quirk, Y.; Ford, D.; Collins, N.; Nguyen, K.; Seal, S.; Tran, T.; Averill, D. et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994, 265, 2088-2090, doi:10.1126/science.8091231.
4. Wooster, R.; Bignell, G.; Lancaster, J.; Swift, S.; Seal, S.; Mangion, J.; Collins, N.; Gregory, S.; Gumbs, C.; Micklem, G. et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, doi:10.1038/378789a0
5. Scully, R.; Chen, J.; Plug, A.; Xiao, Y.; Weaver, D.; Feunteun, J.; Ashley, T.; Livingston, D.M. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997, 88, 265-275, doi:10.1016/S0092-8674(00)81847-4.
6. Sharan, S.K.; Morimatsu, M.; Albrecht, U.; Lim, D.S.; Regel, E.; Dinh, C.; Sands, A; Eichele, G.; Hasty, P.; Bradley, A. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997, 386, 804-810.
7. Gowen, L.C.; Johnson, B.L.; Latour, A.M.; Sulik, K.K.; Koller, B.H. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat. Genet. 1996, 12, 191-194, doi:10.1038/ng0296-191.
8. Ludwig, T.; Chapman, D.L.; Papaioannou, V.E. Targeted mutations of breast cancer susceptibility gene homologs in mice: Lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev. 1997, doi:10.1101/gad.11.10.1226.
9. Chen, J.; Silver, D.P.; Walpita, D.; Cantor, S.B.; Gazdar, A.F.; Tomlinson, G.; Couch, F.J.; Weber, B.L.; Ashley, T.; Livingston, D.M. et al. Stable Interaction between the Products of the BRCA1 and BRCA2 Tumor Suppressor Genes in Mitotic and Meiotic Cells. Mol. Cell 1998, 2, 317-328, doi:10.1016/S1097-2765(00)80276-2.
10. Xia, B.; Sheng, Q.; Nakanishi, K.; Ohashi, A.; Wu, J.; Christ, N.; Liu, X.; Jasin, M.; Couch, F.J.; Livingston, D.M. Control of BRCA2 Cellular and Clinical Functions by a Nuclear Partner, PALB2. Mol. Cell 2006, 22, 719-729, doi:10.1016/j.molcel.2006.05.022.
11. Erkko, H.; Xia, B.; Nikkilä, J.; Schleutker, J.; Syrjäkoski, K.; Mannermaa, A.; Kallioniemi, A.; Pylkäs, K.; Karppinen, S.-M.; Rapakko, K. et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature 2007, 446, 316-319, doi:10.1038/nature05609.
12. Tischkowitz, M.; Xia, B.; Sabbaghian, N.; Reis-Filho, J.S.; Hamel, N.; Li, G.; van Beers, E.H.; Li, L.; Khalil, T. et al. Analysis of PALB2/FANCN-associated breast cancer families. Proc. Natl. Acad. Sci. USA 2007, 104, 6788-6793, doi:10.1073/pnas.0701724104.
13. Dansonka-Mieszkowska, A.; Kluska, A.; Moes, J.; Dabrowska, M.; Nowakowska, D.; Niwinska, A.; Derlatka, P.; Cendrowski, K.; Kupryjanczyk, J. A novel germline PALB2 deletion in Polish breast and ovarian cancer patients. BMC Med. Genet. 2010, doi:10.1186/1471-2350-11-20.
14. Stadler, Z.K.; Salo-Mullen, E.; Sabbaghian, N.; Simon, J.A.; Zhang, L.; Olson, S.H.; Kurtz, R.; Offit, K.; Foulkes, W.D.; Robson, M.E. et al. Germline PALB2 mutation analysis in breast-pancreas cancer families. J. Med. Genet. 2011, 48, 523-525, doi:10.1136/jmg.2010.087379.
15. Southey, M.C.; Goldgar, D.E.; Winqvist, R.; Pylkäs, K.; Couch, F.; Tischkowitz, M.; Foulkes, W.D.; Dennis, J.; Michailidou, K.; van Rensburg, E.J. et al. PALB2, CHEK2 and ATM rare variants and cancer risk: Data from COGS. J. Med. Genet. 2016, doi:10.1136/jmedgenet-2016-103839.
16. Zhang, F.; Ma, J.; Wu, J.; Ye, L.; Cai, H.; Xia, B.; Yu, X. PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response. Curr. Biol. 2009, 19, 524-529, doi:10.1016/j.cub.2009.02.018.
17. Zhang, F.; Fan, Q.; Ren, K.; Andreassen, P.R. PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol. Cancer Res. 2009, 7, 1110-1118, doi:10.1158/1541-7786.MCR-09-0123.
18. Sy, S.M. H.; Huen, M.S. Y.; Chen, J. PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc. Natl. Acad. Sci. USA 2009, 106, 7155-7160, doi:10.1073/pnas.0811159106.
19. Reid, S.; Schindler, D.; Hanenberg, H.; Barker, K.; Hanks, S.; Kalb, R.; Neveling, K.; Kelly, P.; Seal, S.; Freund, M. et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat. Genet. 2007, 39, 162-164, doi:10.1038/ng1947.
20. Xia, B.; Dorsman, J.C.; Ameziane, N.; de Vries, Y.; Rooimans, M.A.; Sheng, Q.; Pals, G.; Errami, A.; Gluckman, E.; Llera, J. et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat. Genet. 2007, 39, 159-161, doi:10.1038/ng1942.
21. Rahman, N.; Seal, S.; Thompson, D.; Kelly, P.; Renwick, A.; Elliott, A.; Reid, S.; Spanova, K.; Barfoot, R.; Chagtai, T. et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Cancer 2007, 39, 165-167, doi:10.1038/ng1959.PALB2.
22. Southey, M.C.; Teo, Z.L.; Dowty, J.G.; Odefrey, F.A.; Park, D.J.; Tischkowitz, M.; Sabbaghian, N.; Apicella, C.; Byrnes, G.B.; Winship, I. et al. A PALB2 mutation associated with high risk of breast cancer. Breast Cancer Res. 2010, 12, R109, doi:10.1186/bcr2796.
23. Antoniou, A.C.; Casadei, S.; Heikkinen, T.; Barrowdale, D.; Pylkäs, K.; Roberts, J.; Lee, A.; Subramanian, D.; De Leeneer, K.; Fostira, F. et al. Breast-cancer risk in families with mutations in PALB2. N. Engl. J. Med. 2014, 371, 497-506, doi:10.1056/NEJMoa1400382.
24. Slavin, T.P.; Maxwell, K.N.; Lilyquist, J.; Vijai, J.; Neuhausen, S.L.; Hart, S.N.; Ravichandran, V.; Thomas, T.; Maria, A.; Villano, D. et al. The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. NPJ Breast Cancer 2017, doi:10.1038/s41523-017-0024-8.
25. Susswein, L.R.; Marshall, M.L.; Nusbaum, R.; Vogel Postula, K.J.; Weissman, S.M.; Yackowski, L.; Vaccari, E.M.; Bissonnette, J.; Booker, J.K.; Cremona, M.L. et al. Pathogenic and likely pathogenic variant prevalence among the first 10, 000 patients referred for next-generation cancer panel testing. Genet. Med. 2015, 18, 1-10, doi:10.1038/gim.2015.166.
26. Silvestri, V.; Zelli, V.; Valentini, V.; Rizzolo, P.; Navazio, A.S.; Coppa, A.; Agata, S.; Oliani, C.; Barana, D.; Castrignan, T. et al. Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene. Cancer 2017, 123, 210-218, doi:10.1002/cncr.30337.
27. Reddy, N.; Malipatil, B.; Kumar, S. A rare case of familial multiple subcutaneous lipomatosis with novel PALB2 mutation and increased predilection to cancers. Hematol. Oncol. Stem Cell Ther. 2016, 9, 154-156, doi:10.1016/j.hemonc.2016.01.001.
28. Pritzlaff, M.; Summerour, P.; McFarland, R.; Li, S.; Reineke, P.; Dolinsky, J.S.; Goldgar, D.E.; Shimelis, H.; Couch, F.J.; Chao, E.C. et al. Male breast cancer in a multi-gene panel testing cohort: Insights and unexpected results. Breast Cancer Res. Treat. 2017, 161, 575-586, doi:10.1007/s10549-016-4085-4.
29. Yang, X.R.; Devi, B.C.R.; Sung, H.; Guida, J.; Mucaki, E.J.; Xiao, Y.; Best, A.; Garland, L.; Xie, Y.; Hu, N. et al. Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia. Breast Cancer Res. Treat. 2017, doi:10.1007/s10549-017-4356-8.
30. Cybulski, C.; Kluźniak, W.; Huzarski, T.; Wokołorczyk, D.; Kashyap, A.; Jakubowska, A.; Szwiec, M.; Byrski, T.; Dębniak, T.; Górski, B. et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: A prospective cohort analysis. Lancet Oncol. 2015, 16, 638-644, doi:10.1016/S1470-2045(15)70142-7.
31. Damiola, F.; Schultz, I.; Barjhoux, L.; Sornin, V.; Dondon, M.G.; Eon-Marchais, S.; Marcou, M.; Caron, O.; Gauthier-Villars, M.; de Pauw, A. et al. Mutation analysis of PALB2 gene in French breast cancer families. Breast Cancer Res. Treat. 2015, 154, 463-471, doi:10.1007/s10549-015-3625-7.
32. Haanpää, M.; Pylkäs, K.; Moilanen, J.S.; Winqvist, R. Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families. BMC Med. Genet. 2013, doi:10.1186/1471-2350-14-82.
33. Casadei, S.; Norquist, B.M.; Walsh, T.; Stray, S.; Mandell, J.B.; Lee, M.K.; Stamatoyannopoulos, J.A.; King, M.C. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res. 2011, 71, 2222-2229, doi:10.1158/0008-5472.CAN-10-3958.
34. Catucci, I.; Milgrom, R.; Kushnir, A.; Laitman, Y.; Paluch-Shimon, S.; Volorio, S.; Ficarazzi, F.; Bernard, L.; Radice, P.; Friedman, E. et al. Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families. Fam. Cancer 2012, 11, 483-491, doi:10.1007/s10689-012-9540-8.
35. McInerney, N.M.; Miller, N.; Rowan, A.; Colleran, G.; Barclay, E.; Curran, C.; Kerin, M.J.; Tomlinson, I.P.; Sawyer, E. Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort. Breast Cancer Res. Treat. 2010, 121, 203-210, doi:10.1007/s10549-009-0540-9.
36. Nakagomi, H.; Sakamoto, I.; Hirotsu, Y.; Amemiya, K.; Mochiduki, H.; Omata, M. Analysis of PALB2 mutations in 155 Japanese patients with breast and/or ovarian cancer. Int. J. Clin. Oncol. 2016, 21, 270-275, doi:10.1007/s10147-015-0906-4.
37. Harinck, F.; Kluijt, I.; van Mil, S.E.; Waisfisz, Q.; van Os, T.A.M.; Aalfs, C.M.; Wagner, A.; Olderode-Berends, M.; Sijmons, R.H.; Kuipers, E.J. et al. Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated. Eur. J. Hum. Genet. 2012, 20, 577-579, doi:10.1038/ejhg.2011.226.
38. Norquist, B.M.; Harrell, M.I.; Brady, M.F.; Walsh, T.; Lee, M.K.; Gulsuner, S.; Bernards, S.S.; Casadei, S.; Yi, Q.; Burger, R.A. et al. Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol. 2015, 6460, 1-9, doi:10.1001/jamaoncol.2015.5495.
39. Walsh, T.; Casadei, S.; Lee, M.K.; Pennil, C.C.; Nord, A.S.; Thornton, A.M.; Roeb, W.; Agnew, K.J.; Stray, S.M.; Wickramanayake, A. et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc. Natl. Acad. Sci. USA 2011, 108, 18032-18037, doi:10.1073/pnas.1115052108.
40. Pennington, K.P.; Walsh, T.; Harrell, M.I.; Lee, M.K.; Pennil, C.C.; Rendi, M.H.; Thornton, A.; Norquist, B.M.; Casadei, S.; Nord, A.S. et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin. Cancer Res. 2014, 20, 764-775, doi:10.1158/1078-0432.CCR-13-2287.
41. Kotsopoulos, J.; Sopik, V.; Rosen, B.; Fan, I.; McLaughlin, J.R.; Risch, H.; Sun, P.; Narod, S.A.; Akbari, M.R. Frequency of germline PALB2 mutations among women with epithelial ovarian cancer. Fam. Cancer 2017, 16, 29-34, doi:10.1007/s10689-016-9919-z.
42. Salo-Mullen, E.E.; O’Reilly, E.; Kelsen, D.; Ashraf, A.M.; Lowery, M.; Yu, K.; Reidy, D.; Epstein, A.S.; Lincoln, A.; Saldia, A. et al. Identification of Germline Genetic Mutations in Pancreatic with pancreatic cancer. Cancer 2015, 121, 4382-4388, doi:10.1002/cncr.29664.
43. Waddell, N; Pajic, M; Patch, A; Chang, D; Kassahn, K, Bailey, P; Johns, A; Miller, D; Nones, K; Quek, K. et al Whole genomes redefine the mutational landscape of pancreatic cancer. Obs. Gynecol. 2015, 125, 628-635, doi:10.1097/AOG.0000000000000696.
44. Slater, E.P.; Langer, P.; Niemczyk, E.; Strauch, K.; Butler, J.; Habbe, N.; Neoptolemos, J.P.; Greenhalf, W.; Bartsch, D.K. PALB2 mutations in European familial pancreatic cancer families. Clin. Genet. 2010, 78, 490-494, doi:10.1111/j.1399-0004.2010.01425.x.
45. Jones, S.; Hruban, R.H.; Kamiyama, M.; Borges, M.; Zhang, X.; Parsons, D.W.; Lin, J.C.H.; Palmisano, E.; Brune, K.; Jaffee, E.M. et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009, doi:10.1126/science.1171202.
46. Hofstatter, E.W. PALB2 mutations in familial breast and pancreatic cancer. Fam. Cancer 2013, 10, 1-10, doi:10.1007/s10689-011-9426-1.PALB2.
47. Takai, E.; Yachida, S.; Shimizu, K.; Furuse, J.; Kubo, E.; Ohmoto, A.; Suzuki, M.; Hruban, R.H.; Okusaka, T.; Morizane, C. et al. Germline mutations in Japanese familial pancreatic cancer patients. Oncotarget 2016, doi:10.18632/oncotarget.12490.
48. Schneider, R.; Slater, E.P.; Sina, M.; Habbe, N.; Fendrich, V.; Matthäi, E.; Langer, P.; Bartsch, D.K. German national case collection for familial pancreatic cancer (FaPaCa): Ten years experience. Fam. Cancer 2011, 10, 323-330, doi:10.1007/s10689-010-9414-x.
49. Ghiorzo, P.; Pensotti, V.; Fornarini, G.; Sciallero, S.; Battistuzzi, L.; Belli, F.; Bonelli, L.; Borgonovo, G.; Bruno, W.; Gozza, A. et al. Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy. Fam. Cancer 2012, 11, 41-47, doi:10.1007/s10689-011-9483-5.
50. Lu, C.; Xie, M.; Wendl, M.C.; Wang, J.; McLellan, M.D.; Leiserson, M.D.M.; Huang, K.-L.; Wyczalkowski, M. A; Jayasinghe, R.; Banerjee, T. et al. Patterns and functional implications of rare germline variants across 12 cancer types. Nat. Commun. 2015, doi:10.1038/ncomms10086.
51. Pritchard, C.C.; Mateo, J.; Walsh, M.F.; De Sarkar, N.; Abida, W.; Beltran, H.; Garofalo, A.; Gulati, R.; Carreira, S.; Eeles, R. et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N. Engl. J. Med. 2016, 375, 443-453, doi:10.1056/NEJMoa1603144.
52. Pearlman, R.; Frankel, W.L.; Swanson, B.; Zhao, W.; Yilmaz, A.; Miller, K.; Bacher, J.; Bigley, C.; Nelsen, L.; Goodfellow, P.J. et al. Prevention Initiative Study Group Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. JAMA Oncol. 2016, 354, 2751-2763, doi:10.1001/jamaoncol.2016.5194.
53. Sahasrabudhe, R.; Lott, P.; Bohorquez, M.; Toal, T.; Estrada, A.P.; Suarez, J.J.; Brea-Fernández, A.; Cameselle-Teijeiro, J.; Pinto, C.; Ramos, I. et al. Germline Mutations in PALB2, BRCA1, and RAD51C, Which Regulate DNA Recombination Repair, in Patients with Gastric Cancer. Gastroenterology 2017, 152, 983-986, doi:10.1053/j.gastro.2016.12.010.
54. Pilié, P.G.; Johnson, A.M.; Hanson, K.L.; Dayno, M.E.; Kapron, A.L.; Stoffel, E.M.; Cooney, K.A. Germline genetic variants in men with prostate cancer and one or more additional cancers. Cancer 2017, doi:10.1002/cncr.30817.
55. Blanco, A.; de la Hoya, M.; Osorio, A.; Diez, O.; Miramar, M.D.; Infante, M.; Martinez-Bouzas, C.; Torres, A.; Lasa, A.; Llort, G. et al. Analysis of PALB2 Gene in BRCA1/BRCA2 Negative Spanish Hereditary Breast/Ovarian Cancer Families with Pancreatic Cancer Cases. PLoS ONE 2013, doi:10.1371/journal.pone.0067538.
56. Li, Y.T.; Jiang, W.H.; Wang, X.W.; Zhang, M.S.; Zhang, C.G.; Yi, L.N.; WuwaliKhan, F.; Ayoufu, A.; Ou, J.H. PALB2 mutations in breast cancer patients from a multi-ethnic region in northwest China. Eur. J. Med. Res. 2015, 20, 1-5, doi:10.1186/s40001-015-0182-9.
57. Foo, T.K.; Tischkowitz, M.; Simhadri, S.; Boshari, T.; Zayed, N.; Burke, K.A.; Berman, S.H.; Blecua, P.; Riaz, N.; Huo, Y. et al. Compromised BRCA1-PALB2 interaction is associated with breast cancer risk. Oncogene 2017, doi:10.1038/onc.2017.46.
58. Heikkinen, T.; Kärkkäinen, H.; Aaltonen, K.; Milne, R.L.; Heikkilä, P.; Aittomäki, K.; Blomqvist, C.; Nevanlinna, H. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clin. Cancer Res. 2009, 15, 3214-3222, doi:10.1158/1078-0432.CCR-08-3128.
59. Tischkowitz, M.; Xia, B. PALB2/FANCN: Recombining cancer and fanconi anemia. Cancer Res. 2010, 70, 7353-7359, doi:10.1158/0008-5472.CAN-10-1012.
60. Lefebvre, C.; Bachelot, T.; Filleron, T.; Pedrero, M.; Campone, M.; Soria, J.C.; Massard, C.; Lévy, C.; Arnedos, M.; Lacroix-Triki, M. et al. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. PLoS Med. 2016, 13, 1-18, doi:10.1371/journal.pmed.1002201.
61. Villarroel, M.C.; Rajeshkumar, N. V; Garrido-Laguna, I.; De Jesus-Acosta, A.; Jones, S.; Maitra, A.; Hruban, R.H.; Eshleman, J.R.; Klein, A.; Laheru, D. et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol. Cancer Ther. 2011, 10, 3-8, doi:10.1158/1535-7163.MCT-10-0893.
62. Xiao, H.; Zhang, K.J.; Xia, B. Defects of FA/BRCA pathway in lymphoma cell lines. Int. J. Hematol. 2009, 88, 543-550, doi:10.1007/s12185-008-0199-8.
63. Spugnesi, L.; Gabriele, M.; Scarpitta, R.; Tancredi, M.; Maresca, L.; Gambino, G.; Collavoli, A.; Aretini, P.; Bertolini, I.; Salvadori, B. et al. Germline Mutations in DNA Repair Genes May Predict Neoadjuvant Therapy Response in Triple Negative Breast Patients. Genes Chromosomes Cancer 2016, 55, 915-924, doi:10.1002/gcc.22389.
64. Goodall, J.; Mateo, J.; Yuan, W.; Mossop, H.; Porta, N.; Miranda, S.; Perez-lopez, R.; Dolling, D.; Robinson, D.R.; Sandhu, S. et al. Circulating Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer Discov. 2017, doi:10.1158/2159-8290.CD-17-0261.
65. Li, F.; Zhou, J.; Xu, M.; Yuan, G. Investigation on the formation, conversion and bioactivity of a Gquadruplex structure in the PALB2 gene. Int. J. Biol. Macromol. 2016, 83, 242-248, doi:10.1016/j.ijbiomac.2015.11.069.
66. Rhodes, D.; Lipps, H. G-quadruplex and their regulatory roles in biology. Nucleic Acids Res. 2015, 43, 8627-8637, doi:10.1093/nar/gkv862.
67. Simonsson, T.; Pecinka, P.; Kubista, M. DNA tetraplex formation in the control region of c-myc. Nucleic Acids Res. 1998, 26, 1167-1172, doi:10.1093/nar/26.5.1167.
68. De Armond, R.; Wood, S.; Sun, D.; Hurley, L.H.; Ebbinghaus, S.W. Evidence for the presence of a guanine quadruplex forming region within a polypurine tract of the hypoxia inducible factor 1α promoter. Biochemistry 2005, 44, 16341-16350, doi:10.1021/bi051618u.
69. Scott, C.M.; Joo, J.H.E.; O’Callaghan, N.; Buchanan, D.D.; Clendenning, M.; Giles, G.G.; Hopper, J.L.; Wong, E.M.; Southey, M.C. Methylation of breast cancer predisposition genes in early-onset breast cancer: Australian breast cancer family registry. PLoS ONE 2016, 11, 1-13, doi:10.1371/journal.pone.0165436.
70. Potapova, A.; Hoffman, A.M.; Godwin, A.K.; Al-Saleem, T.; Cairns, P. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. Cancer Res. 2008, 68, 998-1002, doi:10.1158/0008-5472.CAN-07-2418.
71. Rose, P.W.; Prlić, A.; Bi, C.; Bluhm, W.F.; Christie, C.H.; Dutta, S.; Green, R.K.; Goodsell, D.S.; Westbrook, J.D.; Woo, J. et al. The RCSB Protein Data Bank: Views of structural biology for basic and applied research and education. Nucleic Acids Res. 2015, 43, D345-D356, doi:10.1093/nar/gku1214.
72. Rose, P.W.; Prli, A.; Altunkaya, A.; Bi, C.; Bradley, A.R.; Christie, C.H.; Di Costanzo, L.; Duarte, J.M.; Dutta, S.; Feng, Z. et al. The RCSB protein data bank: Integrative view of protein, gene and 3D structural information. Nucleic Acids Res. 2017, 45, D271-D281, doi:10.1093/nar/gkw1000.
73. Oliver, A.W.; Swift, S.; Lord, C.J.; Ashworth, A.; Pearl, L.H. Structural basis for recruitment of BRCA2 by PALB2. EMBO Rep. 2009, 10, 990-996, doi:10.1038/embor.2009.126.
74. Landschulz, W.; Johnson, P.; McKnight, S. The leucine zipper: A hypothetical structure common to a new class of DNA binding proteins. Science 1988, 240, 1759-1764, doi:10.1126/science.3289117.
75. Lupas, A. Coiled coils: New structures and new functions. Trends Biochem. Sci. 1996, 21, 375-382, doi:10.1016/0968-0004(96)10052-10059.
76. Lupas, A; Van Dyke, M.; Stock, J. Predicting coiled coils from protein sequences. Science 1991, 252, 1162-1164, doi:10.1126/science.252.5009.1162.
77. O’Shea, E.K.; Lumb, K.J.; Kim, P.S. Peptide “Velcro”: Design of a heterodimeric coiled coil. Curr. Biol. 1993, 3, 658-667, doi:10.1016/0960-9822(93)90063-T.
78. Buisson, R.; Masson, J.Y. PALB2 self-interaction controls homologous recombination. Nucleic Acids Res. 2012, 40, 10312-10323, doi:10.1093/nar/gks807.
79. Sy, S.M. H.; Huen, M.S. Y.; Zhu, Y.; Chen, J. PALB2 regulates recombinational repair through chromatin association and oligomerization. J. Biol. Chem. 2009, 284, 18302-18310, doi:10.1074/jbc.M109.016717.
80. Dray, E.; Etchin, J.; Wiese, C.; Saro, D.; Williams, G.J.; Yu, X.; Galkin, V.E.; Liu, D.; Tsai, M.M-H S. et al. Enhancement of the RAD51 Recombinase Activity by the Tumor Suppressor PALB2. Nat. Struct. Mol. Biol. 2011, 17, 1255-1259, doi:10.1038/nsmb.1916.Enhancement.
81. Buisson, R.; Dion-Côté, A.-M.; Coulombe, Y.; Launay, H.; Cai, H.; Stasiak, A.Z.; Stasiak, A.; Xia, B.; Masson, J.-Y. Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat. Struct. Mol. Biol. 2010, 17, 1247-1254, doi:10.1038/nsmb.1915.
82. Bleuyard, J.-Y.; Buisson, R.; Masson, J.-Y.; Esashi, F. ChAM, a novel motif that mediates PALB2 intrinsic chromatin binding and facilitates DNA repair. EMBO Rep. 2012, 13, 135-141, doi:10.1038/embor.2011.243.
83. Wu, X.H.; Chen, R.C.; Gao, Y.; Wu, Y.D. The effect of Asp-His-Ser/Thr-Trp tetrad on the thermostability of WD40-repeat proteins. Biochemistry 2010, 49, 10237-10245, doi:10.1021/bi101321y.
84. Smith, T.F.; Gaitatzes, C.; Saxena, K.; Neer, E.J. The WD repeat: A common architecture for diverse functions. Trends Biochem. Sci. 1999, 24, 181-185, doi:10.1016/S0968-0004(99)01384-5.
85. Pauty, J.; Couturier, A.M.; Rodrigue, A.; Caron, M.C.; Coulombe, Y.; Dellaire, G.; Masson, J.Y. Cancercausing mutations in the tumor suppressor PALB2 reveal a novel cancer mechanism using a hidden nuclear export signal in the WD40 repeat motif. Nucleic Acids Res. 2017, 45, 2644-2657, doi:10.1093/nar/gkx011.
86. Taniguchi, T.; Andrea, A.D. D. Molecular pathogenesis of Fanconi anemia : Recent progress. Blood 2006, 107, 4223-4234, doi:10.1182/blood-2005-10-4240.
87. Wang, W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat. Rev. Genet 2007, 8, 735-748, doi:10.1038/nrg2159.
88. Dong, H.; Nebert, D.W.; Bruford, E.A.; Thompson, D.C.; Joenje, H.; Vasiliou, V. Update of the human and mouse Fanconi anemia genes. Hum. Genom. 2015, doi:10.1186/s40246-015-0054-y.
89. Castella, M.; Jacquemont, C.; Thompson, E.L.; Yeo, J.E.; Cheung, R.S.; Huang, J.W.; Sobeck, A.; Hendrickson, E.A.; Taniguchi, T. FANCI Regulates Recruitment of the FA Core Complex at Sites of DNA Damage Independently of FANCD2. PLoS Genet. 2015, 11, 1-27, doi:10.1371/journal.pgen.1005563.
90. Hira, A.; Yoshida, K.; Sato, K.; Okuno, Y.; Shiraishi, Y.; Chiba, K.; Tanaka, H.; Miyano, S.; Shimamoto, A.; Tahara, H. et al. Mutations in the gene encoding the E2 conjugating enzyme UBE2T cause fanconi anemia. Am. J. Hum. Genet. 2015, 96, 1001-1007, doi:10.1016/j.ajhg.2015.04.022.
91. Miles, J.A.; Frost, M.G.; Carroll, E.; Rowe, M.L.; Howard, M.J.; Sidhu, A.; Chaugule, V.K.; Alpi, A.F.; Walden, H. The Fanconi Anemia DNA repair pathway is regulated by an interaction between ubiquitin and the E2-like fold domain of FANCL. J. Biol. Chem. 2015, 290, 20995-21006, doi:10.1074/jbc.M115.675835.
92. Knipscheer, P; Räschle, M; Smogorzewska, A; Enoiu, M; Ho, T; Schärer, O; Elledge, S and Walter, J. The Fanconi anemia pathway promotes replication-dependent DNA interstrand crosslink repair. Science 2010, 23, 83-88, doi:10.1016/j.jdiacomp.2008.01.002.
93. Hodskinson, M.R.G.; Silhan, J.; Crossan, G.P.; Garaycoechea, J.I.; Mukherjee, S.; Johnson, C.M.; Schärer, O.D.; Patel, K.J. Mouse SLX4 Is a Tumor Suppressor that Stimulates the Activity of the Nuclease XPFERCC1 in DNA Crosslink Repair. Mol. Cell 2014, 54, 472-484, doi:10.1016/j.molcel.2014.03.014.
94. Douwel, D; Boonen, R; Long, D; Szypowska, A; Räschle, M; Walter, J and Knipsheer, P. XPF-ERCC1 acts in unhooking DNA interstrand crosslinks in cooperation with FANCD2 and FANCP/SLX4. Mol. cell 2015, 2, 460-471, doi:10.1126/scisignal.274pe36.Insulin.
95. Budzowska, M.; Graham, T.G.; Sobeck, A.; Waga, S.; Walter, J.C. Regulation of the Rev1-pol f complex during bypass of a DNA interstrand cross-link. EMBO J. 2015, 34, 1971-1985, doi:10.15252/embj.
96. Matsuoka, S.; Ballif, B.A.; Smogorzewska, A.; McDonald, E.R.; Hurov, K.E.; Luo, J.; Bakalarski, C.E.; Zhao, Z.; Solimini, N.; Lerenthal, Y. et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007, 316, 1160-1166, doi:10.1126/science.1140321.
97. Uziel, T.; Lerenthal, Y.; Moyal, L.; Andegeko, Y.; Mittelman, L.; Shiloh, Y. Requirement of the MRN complex for ATP activation by DNA damage. EMBO J. 2003, 22, 5612-5621
98. Kumagai, A.; Lee, J.; Yoo, H.Y.; Dunphy, W.G. TopBP1 activates the ATR-ATRIP complex. Cell 2006, 124, 943-955, doi:10.1016/j.cell.2005.12.041.
99. Liu, T.; Huang, J. DNA End Resection: Facts and Mechanisms. Genom. Proteom. Biol. 2016, 14, 126-130, doi:10.1016/j.gpb.2016.05.002.
100. Li, J.; Holzschu, D.L.; Sugiyama, T. PCNA is efficiently loaded on the DNA recombination intermediate to modulate polymerase δ, η, and ζ activities. Proc. Natl. Acad. Sci. USA 2013, 110, 7672-7677, doi:10.1073/pnas.1222241110.
101. Mcllwraith, M.J.; Vaisman, A.; Liu, Y.; Fanning, E.; Woodgate, R.; West, S.C. Human DNA polymerase η promotes DNA synthesis from strand invasion intermediates of homologous recombination. Mol. Cell 2005, 20, 783-792, doi:10.1016/j.molcel.2005.10.001.
102. Sneeden, J.L.; Grossi, S.M.; Tappin, I.; Hurwitz, J.; Heyer, W.D. Reconstitution of recombination-associated DNA synthesis with human proteins. Nucleic Acids Res. 2013, 41, 4913-4925, doi:10.1093/nar/gkt192.
103. Buisson, R.; Niraj, J.; Pauty, J.; Maity, R.; Zhao, W.X.; Coulombe, Y.; Sung, P.; Masson, J.-Y. Breast cancer proteins PALB2 and BRCA2 stimulate polymerase η in recombination-associated DNA synthesis at blocked replication forks. Cell Rep. 2014, 76, 211-220, doi:10.1016/j.celrep.2014.01.009.
104. Paliwal, S.; Kanagaraj, R.; Sturzenegger, A.; Burdova, K.; Janscak, P. Human RECQ5 helicase promotes repair of DNA double-strand breaks by synthesis-dependent strand annealing. Nucleic Acids Res. 2014, 42, 2380-2390, doi:10.1093/nar/gkt1263.
105. Fekairi, S.; Scaglione, S.; Chahwan, C.; Taylor, E.R.; Tissier, A.; Coulon, S.; Dong, M.Q.; Ruse, C.; Yates, J.R.; Russell, P. et al. Human SLX4 Is a Holliday Junction Resolvase Subunit that Binds Multiple DNA Repair/Recombination Endonucleases. Cell 2009, 138, 78-89, doi:10.1016/j.cell.2009.06.029.
106. You, Z.; Bailis, J.M. DNA damage and decisions: CtIP coordinates DNA repair and cell cycle checkpoints. Trends Cell Biol. 2010, 20, 402-409, doi:10.1016/j.tcb.2010.04.002.
107. Buisson, R.; Niraj, J.; Rodrigue, A.; Ho, C.K.; Kreuzer, J.; Foo, T.K.; Hardy, E.J.L.; Dellaire, G.; Haas, W.; Xia, B. et al. Coupling of Homologous Recombination and the Checkpoint by ATR. Mol. Cell 2017, 65, 336-346, doi:10.1016/j.molcel.2016.12.007.
108. Guo, Y.; Feng, W.; Sy, S.M. H.; Huen, M.S. Y. ATM-dependent phosphorylation of the Fanconi anemia protein PALB2 promotes the DNA damage response. J. Biol. Chem. 2015, 290, 27545-27556, doi:10.1074/jbc.M115.672626.
109. Ahlskog, J.K.; Larsen, B.D.; Achanta, K.; Sørensen, C.S. ATM/ATR-mediated phosphorylation of PALB 2 promotes RAD51 function. EMBO Rep. 2016, 17, 1-11, doi:10.15252/embr.201541455.
110. Escribano-Díaz, C.; Orthwein, A.; Fradet-Turcotte, A.; Xing, M.; Young, J.T.F.; Tkáč, J.; Cook, M.A.; Rosebrock, A.P.; Munro, M.; Canny, M.D. et al. A Cell Cycle-Dependent Regulatory Circuit Composed of 53BP1-RIF1 and BRCA1-CtIP Controls DNA Repair Pathway Choice. Mol. Cell 2013, 49, 872-883, doi:10.1016/j.molcel.2013.01.001.
111. Orthwein, A.; Noordermeer, S.M.; Wilson, M.D.; Landry, S.; Enchev, R.I.; Sherker, A.; Munro, M.; Pinder, J.; Salsman, J.; Dellaire, G. et al. A mechanism for the suppression of homologous recombination in G1 cells. Nature 2015, doi:10.1038/nature16142.
112. Ma, J.; Cai, H.; Wu, T.; Sobhian, B.; Huo, Y.; Alcivar, A.; Mehta, M.; Cheung, K.L.; Ganesan, S.; Kong, A.-N.T. et al. PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function. Mol. Cell. Biol. 2012, 32, 1506-1517, doi:10.1128/MCB.06271-11.
113. Hayakawa, T.; Zhang, F.; Hayakawa, N.; Ohtani, Y.; Shinmyozu, K.; Nakayama, J.; Andreassen, P.R. MRG15 binds directly to PALB2 and stimulates homology-directed repair of chromosomal breaks. J. Cell Sci. 2010, 123, 1124-1130, doi:10.1242/jcs.060178.
114. Sy, S.M.H.; Huen, M.S.Y.; Chen, J. MRG15 is a novel PALB2-interacting factor involved in homologous recombination. J. Biol. Chem. 2009, 284, 21127-21131, doi:10.1074/jbc.C109.023937.
115. Anantha, R.W.; Alcivar, A.L.; Ma, J.; Cai, H.; Simhadri, S.; Ule, J.; König, J.; Xia, B. Requirement of Heterogeneous Nuclear Ribonucleoprotein C for BRCA Gene Expression and Homologous Recombination. PLoS ONE 2013, doi:10.1371/journal.pone.0061368.
116. Doyon, Y.; Selleck, W.; Lane, W.S.; Tan, S.; Côté, J. Structural and functional conservation of the NuA4 histone acetyltransferase complex from yeast to humans. Mol. Cell. Biol. 2004, 24, 1884-1896, doi:10.1128/MCB.24.5.1884.
117. Sivanand, S.; Rhoades, S.; Jiang, Q.; Lee, J.V.; Benci, J.; Zhang, J.; Yuan, S.; Viney, I.; Zhao, S.; Carrer, A. et al. Nuclear Acetyl-CoA Production by ACLY Promotes Homologous Recombination. Mol. Cell 2017, doi:10.1016/j.molcel.2017.06.008.
118. Tominaga, K.; Kirtane, B. MRG15 regulates embryonic development and cell proliferation. Mol. Cell. Biol. 2005, 25, 2924-2937, doi:10.1128/MCB.25.8.2924.
119. Garcia, S.N.; Kirtaneb, B.M.; Podlutskya, A.J.; Pereira-Smitha, O.M.; Tominaga, K. Mrg15 null and heterozygous mouse embryonic fibroblasts exhibit DNA repair defects post exposure to gamma ionizing radiation. FEBS Lett. 2007, 581, 5275-5281.
120. Bleuyard, J.-Y.; Fournier, M.; Nakato, R.; Couturier, A.M.; Katou, Y.; Ralf, C.; Hester, S.S.; Dominguez, D.; Rhodes, D.; Humphrey, T.C. et al. MRG15-mediated tethering of PALB2 to unperturbed chromatin protects active genes from genotoxic stress. Proc. Natl. Acad. Sci. USA 2017, doi:10.1073/pnas.1620208114.
121. Martrat, G.; Maxwell, C.A.; Tominaga, E.; Bonifaci, N.; Gómez-baldó, L.; Bogliolo, M.; Lázaro, C.; Blanco, I.; Brunet, J.; Aguilar, H. Exploring the link between MORF4L1 and risk of breast cancer. Breast Cancer Res. 2011, 13, 1-14.
122. Rio Frio, T.; Haanpaa, M.; Pouchet, C.; Pylkas, K.; Vuorela, M.; Tischkowitz, M.; Winqvist, R.; Foulkes, W.D. Mutation analysis of the gene encoding the PALB2-binding protein MRG15 in BRCA1/2-negative breast cancer families. J Hum Genet 2010, 55, 842-843, doi:10.1038/jhg.2010.112.
123. Mladenov, E.; Magin, S.; Soni, A.; Iliakis, G. DNA double-strand-break repair in higher eukaryotes and its role in genomic instability and cancer: Cell cycle and proliferation-dependent regulation. Semin. Cancer Biol. 2016, 37, 51-64, doi:10.1016/j.semcancer.2016.03.003.
124. Arcas, A.; Fernández-Capetillo, O.; Cases, I.; Rojas, A.M. Emergence and evolutionary analysis of the human DDR network: Implications in comparative genomics and downstream analyses. Mol. Biol. Evol. 2014, 31, 940-961, doi:10.1093/molbev/msu046.
125. Prakash, L.; Taillon-Miller, P. Effects of the rad52 gene on sister chromatid recombination in Saccharomyces cerevisiae. Curr. Genet. 1981, 3, 247-250, doi:10.1007/BF00429828.
126. Haber, J.E.; Hearn, M. Rad52-independent mitotic gene conversion in Saccharomyces cerevisiae frequently results in chromosomal loss. Genetics 1985, 111, 7-22.
127. Shinohara, A.; Shinohara, M.; Ohta, T.; Matsuda, S.; Ogawa, T. Rad52 forms ring structures and co-operates with RPA in single-strand DNA annealing. Genes Cells 1998, 3, 145-156, doi:10.1046/j.1365-2443.1998.00176.x.
128. New, J.H.; Sugiyama, T.; Zaitseva, E.; Kowalczykowski, S.C. Rad52 protein stimulates DNA strand exchange by Rad51 and replication protein A. Nature 1998, 391, 407-410, doi:10.1038/34950.
129. Sugiyama, T.; New, J.H.; Kowalczykowski, S.C. DNA annealing by Rad52 Protein is stimulated by specific interaction with the complex of replication protein A and single-stranded DNA. Proc. Natl. Acad. Sci. USA 1998, 95, 6049-6054, doi:10.1073/pnas.95.11.6049.
130. Game, J.C.; Mortimer, R.K. A genetic study of X-ray sensitive mutants in yeast. Mutat. Res. Fundam. Mol. Mech. Mutagen. 1974, 24, 281-292, doi:10.1016/0027-5107(74)90176-6.
131. Pâques, F.; Haber, J.E. Multiple pathways of recombination induced by double-strand breaks in Saccharomyces cerevisiae. Microbiol. Mol. Biol. Rev. 1999, 63, 349-404.
132. Rijkers, T.; Van Den Ouweland, J.; Morolli, B.; Rolink, A.G.; Baarends, W.M.; Van Sloun, P.P. H.; Lohman, P.H. M.; Pastink, A. Targeted Inactivation of Mouse RAD52 Reduces Homologous Recombination but Not Resistance to Ionizing Radiation. Mol. Cell. Biol. 1998, 18, 6423-6429, doi:10.1128/MCB.18.11.6423.
133. Stark, J.M.; Pierce, A.J.; Oh, J.; Pastink, A.; Jasin, M. Genetic steps of mammalian homologous repair with distinct mutagenic consequences. Mol. Cell. Biol. 2004, 24, 9305-9316, doi:10.1128/MCB.24.21.9305-9316.2004.
134. Bennardo, N.; Cheng, A.; Huang, N.; Stark, J.M. Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair. PLoS Genet. 2008, doi:10.1371/journal.pgen.1000110.
135. Ochs, F.; Somyajit, K.; Altmeyer, M.; Rask, M.-B.; Lukas, J.; Lukas, C. 53BP1 fosters fidelity of homologydirected DNA repair. Nat. Struct. Mol. Biol. 2016, 23, 714-21, doi:10.1038/nsmb.3251.
136. Davis, A.P.; Symington, L.S. The yeast recombinational repair protein Rad59 interacts with Rad52 and stimulates single-strand annealing. Genetics 2001, 159, 515-525.
137. Jensen, R.B.; Carreira, A.; Kowalczykowski, S.C. Purified human BRCA2 stimulates RAD51-mediated recombination. Nature 2010, 467, 678-683, doi:10.1038/nature09399.
138. Jensen, R.B. BRCA2: One small step for DNA repair, one giant protein purified. Yale J. Biol. Med. 2013, 86, 479-489.
139. Liu, J.; Doty, T.; Gibson, B.; Heyer, W.-D. Human BRCA2 protein promotes RAD51 filament formation on RPA-covered single-stranded DNA. Nat. Struct. Mol. Biol. 2010, 17, 1260-1262, doi:10.1038/nsmb.1904.
140. Moriel-Carretero, M.; Aguilera, A. A Postincision-Deficient TFIIH Causes Replication Fork Breakage and Uncovers Alternative Rad51-or Pol32-Mediated Restart Mechanisms. Mol. Cell 2010, 37, 690-701, doi:10.1016/j.molcel.2010.02.008.
141. Murphy, A.K.; Fitzgerald, M.; Ro, T.; Kim, J.H.; Rabinowitsch, A.I.; Chowdhury, D.; Schildkraut, C.L.; Borowiec, J.A. Phosphorylated RPA recruits PALB2 to stalled DNA replication forks to facilitate fork recovery. J. Cell Biol. 2014, 206, 493-507, doi:10.1083/jcb.201404111.
142. Feng, Z.; Scott, S.P.; Bussen, W.; Sharma, G.G.; Guo, G.; Pandita, T.K.; Powell, S.N. Rad52 inactivation is synthetically lethal with BRCA2 deficiency. Proc. Natl. Acad. Sci. USA 2011, 108, 686-691, doi:10.1073/pnas.1010959107.
143. Lok, B.H.; Carley, A C.; Tchang, B.; Powell, S.N. RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination. Oncogene 2013, 32, 3552-3558, doi:10.1038/onc.2012.391.
144. Park, J.-Y.; Singh, T.R.; Nassar, N.; Zhang, F.; Freund, M.; Hanenberg, H.; Meetei, A.R.; Andreassen, P.R. Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair. Oncogene 2014, 33, 4803-4812, doi:10.1038/onc.2013.421.
145. Poumpouridou N.; Kroupis, C. Hereditary breast cancer: Beyond BRCA genetic analysis; PALB2 emerges. Clin. Chem. Lab. Med. 2012, 50, 423-434.
146. Shah, S.P.; Morin, R.D.; Khattra, J.; Prentice, L.; Pugh, T.; Burleigh, A.; Delaney, A.; Gelmon, K.; Guliany, R.; Senz, J. et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009, 461, 809-813, doi:10.1038/nature08489.
147. Obermeier, K.; Sachsenweger, J.; Friedl, T.W. P.; Pospiech, H.; Winqvist, R.; Wiesmüller, L. Heterozygous PALB2 c.1592delT mutation channels DNA double-strand break repair into error-prone pathways in breast cancer patients. Oncogene 2015, doi:10.1038/onc.2015.448.
148. Huang, F.; Goyal, N.; Sullivan, K.; Hanamshet, K.; Patel, M.; Mazina, O.M.; Wang, C.X.; An, W.F.; Spoonamore, J.; Metkar, S. et al. Targeting BRCA1-and BRCA2-deficient cells with RAD52 small molecule inhibitors. Nucleic Acids Res. 2016, 44, 4189-4199, doi:10.1093/nar/gkw087.